{"brief_title": "A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis", "brief_summary": "To assess the safety of intravenous itraconazole compared to amphotericin B in HIV positive or negative persons with blastomycosis or histoplasmosis.", "detailed_description": "Patients are randomized to receive IV itraconazole for 2 days, then either itraconazole daily for 5 days or amphotericin B daily for 7 days. IV treatment is followed by consolidation with oral itraconazole for up to 1 year.", "condition": "Blastomycosis", "intervention_type": "Drug", "intervention_name": "Amphotericin B", "criteria": "Inclusion Criteria Patients must have: - HIV positive or negative status. - Blastomycosis or histoplasmosis. - Life expectancy of at least 1 week. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Liver disease. - Self-limiting fungal disease. - Very severe fungal disease such as meningeal involvement. - Acute respiratory disease. Concurrent Medication: Excluded at any time: - Terfenadine. - Astemizole. - Oral midazolam. - Triazolam. - Cisapride. - Phenytoin. - Phenobarbital. - Rifampin. - Rifabutin. Excluded during oral consolidation: - H2 blockers. - Chronic antacids. - Omeprazole. - Lansoprazole. Patients with the following prior condition are excluded: Hypersensitivity to azole antifungals. Prior Medication: Excluded at any time: More than 3 days of amphotericin B, fluconazole, or ketoconazole. Excluded within 2 weeks prior to study entry: - Phenytoin. - Phenobarbital. - Rifampin. - Rifabutin.", "gender": "All", "minimum_age": "13 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00002159.xml"}